Abeona Therapeutics Inc. (ABEO) Stock: Price, Forecast & Analyst Target
Abeona Therapeutics Inc. (ABEO) — MoonshotScore 17/100 (Weak band), calculated Nov 18, 2026. Price $2.45 (-10.26%), as of the Nov 19, 2026 trading session; market cap $151M.
Educational signal · not a buy or sell recommendation · How to read this
Abeona Therapeutics Inc. · ABEO · NASDAQ
Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing gene and cell therapies for rare genetic diseases.
Price as of Nov 19, 2026
Key Statistics
MoonshotScore v2 · Abeona Therapeutics (ABEO)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Only growth holds up — quality and the balance sheet are near the sector floor; far more to fix here than to build on, and it’s expensive on top. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone and losses on top of negative retained earnings. Business Quality: Poor; Financial Safety: Strained; Valuation: Full; Growth Durability: Flat; Momentum: Slipping.
- quarterly revenue $5M (Q4 FY2025, quarter ended Dec 2025)
- EPS beat 7 of the last 8 reports
- Altman Z -4.46 · Piotroski F 3
Holding back: weak fundamentals, weak price trend
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 17 | Weak | |
| 17 | Weak | |
| 17 | Weak | |
| 17 | Weak | |
| 17 | Weak | |
| 17 | Weak |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $2.45 | |
| Change on the day | -10.26% | |
| 52-week range | $2.09 – $7.65 | |
| Market capitalisation | $151M | — |
| Price / earnings (trailing) | 20.16 | |
| Shares traded on the day | 1.91M |
Price & events
Other perspectives
Council score for Abeona Therapeutics (ABEO): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
6 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Nov 18, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Abeona Therapeutics (ABEO), and what does it report?
Short answer
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Abeona Therapeutics Inc. (ABEO) is listed on NASDAQ. It employs 226 people and is led by Vishwas Seshadri. In Q4 FY2025 it reported revenue of $5M and net income of -$20M. The market values it at $151M.
What do the latest results show for Abeona Therapeutics (ABEO)?
Short answer · as of
The most recent reported quarter, Q4 FY2025, carried revenue of $5M. Against analyst estimates the company has EPS beat 7 of the last 8 reports.
Quarterly income statement — 3 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q4 FY2025 | $5M | -$20M | — |
| Q1 FY2026 | $9M | -$17M | -$0.30 (diluted) |
| Q2 FY2026 | $11M | -$20M | -$0.35 (diluted) |
What are the financial strengths and risks for Abeona Therapeutics (ABEO)?
Short answer
What is holding it back is weak fundamentals, weak price trend. The distress and quality screens read Altman Z -4.46 · Piotroski F 3. Trailing ratios: ROE 71.0% · ROA -38.9% · current ratio 5.89.
Data-derived red flags
- Financial-distress signal — its Altman Z-Score of -4.46 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
What should you watch next at Abeona Therapeutics (ABEO)?
Short answer · as of
Current published price targets run low $15.00 · high $21.00 · consensus $17.67 · median $17.00 against a quoted price of $2.45 (as of Nov 19, 2026).
What the records here don't tell us
- No forward revenue or earnings estimate is on file.
- The next earnings date is not yet scheduled in the calendar we read.
- The newest quarter held here (Q4 FY2025) was filed Mar 17, 2026 — 7 months ago.
Checked against the records this page reads, on the dates shown above.
How does Abeona Therapeutics compare with its peers?
Short answer
Abeona Therapeutics's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $13.33 Nov 18, 2026 | $471M | 91 5-pillar Nov 18, 2026 | |
| $9.28 Nov 18, 2026 | $552M | 91 5-pillar Nov 18, 2026 | |
| $3.06 Nov 19, 2026 | $258M | 90 5-pillar Nov 18, 2026 | |
| $42.53 Nov 18, 2026 | $801M | 88 5-pillar Nov 18, 2026 | |
| $11.25 Nov 18, 2026 | $102M | 82 5-pillar Nov 18, 2026 | |
| $15.26 Nov 18, 2026 | $85.5M | 82 5-pillar Nov 18, 2026 | |
| $3.89 Nov 18, 2026 | $169M | 72 5-pillar Nov 18, 2026 | |
| $1.88 Nov 19, 2026 | $178M | 69 5-pillar Nov 18, 2026 | |
| $9.30 Nov 18, 2026 | $546M | 68 5-pillar Nov 18, 2026 | |
| $8.14 Nov 19, 2026 | $796M | 63 5-pillar Nov 18, 2026 | |
| $3.13 Nov 19, 2026 | $481M | 60 5-pillar Nov 18, 2026 | |
| $6.78 Nov 19, 2026 | $541M | 60 5-pillar Nov 18, 2026 | |
| Abeona Therapeutics (ABEO) — this page | $2.45 | $151M | 17 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $15.00 – $21.00
- Consensus target
- $17.67
- Median target
- $17.00
Consensus record · Captured .
Measured against a quoted price of $2.45 (as of Nov 19, 2026).
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Sep 29, 2026
- Transactions
- 23
- Identified insiders
- 7
- Purchases
- 0
- Sales
- 21
- Other transactions
- 2
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held ABEO in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported ABEO in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Abeona Therapeutics (ABEO)?
- Abeona Therapeutics Inc. (ABEO) Presents at Stifel 2026 Healthcare Conference 2026 - Slideshow
- Abeona Therapeutics (ABEO) Stock Sees Fair Value Falls As Zevaskyn Ramp Concerns Grow
- ABEO: In-Licenses Phase 3 Candidate for Eosinophilic Esophagitis
- HC Wainwright & Co. Maintains Buy on Abeona Therapeutics, Lowers Price Target to $18
What Investors Ask About Abeona Therapeutics (ABEO)
These answers are editorial: 1 of these 9 answers is drawn from the ABEO research dossier (written May 7, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.
What does the MoonshotScore mean for ABEO?
ABEO carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.
Is ABEO a good stock to buy?
Stock Expert AI does not rate ABEO buy, sell or hold. Abeona Therapeutics Inc. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the ABEO stock price today?
The last price recorded for Abeona Therapeutics Inc. (ABEO), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the ABEO price target?
The analyst consensus price target for Abeona Therapeutics Inc. (ABEO), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
What are the main risks for ABEO?
Abeona Therapeutics faces several key risks inherent to the biotechnology industry. Clinical trial failures or delays represent a significant risk, as the success of its pipeline programs depends on positive clinical data. Regulatory hurdles and potential disapproval of its gene therapy products also pose a threat. Competition from other companies developing gene and cell therapies could impact its market share.
What are the key factors to evaluate for ABEO?
Abeona Therapeutics Inc. (ABEO) holds a MoonshotScore in the low range. To weigh it, compare the trailing P/E under Price & valuation with the analyst view under Analyst targets & estimates on this page. Not financial advice.
How frequently does ABEO data refresh on this page?
ABEO's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven ABEO's recent stock price performance?
Abeona Therapeutics Inc. (ABEO) moves on earnings results, analyst revisions, sector rotation, and market sentiment. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ABEO overvalued or undervalued right now?
The trailing P/E of Abeona Therapeutics Inc. (ABEO) is listed under Price & valuation, and the analyst consensus target under Analyst targets & estimates, on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 7, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 21 figures on this page — 13 from Financial Modeling Prep (FMP), 7 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
ETFs that hold ABEO
Funds in our ETF coverage that list ABEO among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.
| ETF | Weight | Holdings as of |
|---|---|---|
| Simplify Propel Opportunities ETF (SURI) | 3.28% |